Life
Stealth Biotech Stipple Focuses on ADCs Amid NIH Budget Concerns
Stipple, a biotech firm, is making strides in antibody-drug conjugates (ADCs) while navigating the implications of proposed NIH funding cuts. The approach leverages peptide technology.
Editorial Staff
1 min read
Stipple is positioning itself in the competitive biotech landscape by focusing on antibody-drug conjugates (ADCs), a strategy that may influence market dynamics in therapeutic development.
The company's reliance on peptide technology raises questions about the robustness of the underlying science, particularly as it faces scrutiny from funding bodies like the NIH.
Proposed cuts to NIH funding could have cascading effects on research and development in the biotech sector, potentially impacting innovation and investment in companies like Stipple.